Solid Biosciences (SLDB) Q3 2026 earnings — TrendMatrix coverage

Adjusted EPS

-$0.36

Estimate

-$0.41

Surprise

+12.8%

Score today

5.4/10

Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.

Solid Biosciences (SLDB) reported a narrower loss than forecast — adjusted EPS of -$0.36 against the -$0.41 estimate (a 12.8% beat on a still-unprofitable quarter).

• Solid Biosciences Management to Participate in Guggenheim Healthcare Innovation Conference — fiscal.ai, 2026-11-05
• Solid Biosciences Reports Third Quarter 2026 Financial Results and Provides Business Update — fiscal.ai, 2026-11-04
• Solid Biosciences Q3 R&D Expenses $43.6M vs $38.9M YoY; G&A $14.1M vs $9.2M YoY — benzinga, 2026-11-04

TrendMatrix currently rates SLDB Sell at 5.4/10; no pre/post engine snapshot brackets this report.

2 of the last 4 quarters beat the estimate; this quarter's +12.8% surprise compares with a +5.2% four-quarter average. Next scheduled report: 2027-03-18.

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current price

$6.61

Price target

$16.28

Stop

$6.15

Upside to target

+146.3%

Reward-to-risk

9.8:1

Model outputs from TrendMatrix’s engine as of 2026-11-06 — shown for context, not personalized investment advice.

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry

Biotechnology

Market cap

$662.7M

P/E (fwd)

-3.6

52-week range

$3.79–$11.45

Off 52-week high

42.3%

RSI (14)

60

Volume vs avg

0.35×

Score today

5.4/10